Longboard Pharmaceuticals Provides Corporate Update and Reports Full Year 2021 Financial Results
March 03, 2022 16:05 ET
|
Longboard Pharmaceuticals, Inc.
Initiated the Phase 1b/2a PACIFIC Study, evaluating LP352 in participants with developmental and epileptic encephalopathies (DEEs)LP352 demonstrated statistically significant reduction of epileptiform...